secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0000950170-25-042647
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Biosciences Q4 revenue +56% YoY to $1.2M; net loss widens; Roosevelt deal on track
--------------------------------------------------------------------------------

- Q4 total revenues $1.216M (+56% YoY); FY2024 revenues $5.045M (+13% YoY).
- Net loss attributable to common stockholders Q4 $4.064M ($2.98/share) vs $2.853M in Q4 2023.
- Full-year net loss improved to $7.038M ($3.17/share) from $13.981M in 2023.
- Zola coconut water revenue up 124% in Q4 and 46% for full year.
- Pending merger with Roosevelt Resources; post-close owners get ~90% of shares, Arcadia holders ~10%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017025042647/0000950170-25-042647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017025042647/rkda-20250320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer